Enrique Conterno

Type: Person

Name: Enrique Conterno

First reported Apr 17 2013 - Updated Apr 18 2013 - 1 reports

Lilly diabetes drug dulaglutide meets late-stage study goals

has announced that its experimental diabetes drug dulaglutide achieved the main goal of reducing in people with in two additional late-stage studies.Results from two recently completed Phase III clinical trials for dulaglutide showed that the long-acting ... [Published Diabetes.co.uk - Apr 17 2013]

Entities: Dulaglutide, Eli Lilly & Company, Glycated Hemoglobin

First reported Apr 16 2013 - Updated Apr 17 2013 - 2 reports

Eli Lilly's experimental diabetes drug meets goals

_ Eli Lilly and Co. released more positive news today about its diabetes drug dulaglutide, which it hopes to submit this year for U.S. marketing approval.The experimental drug met its efficacy goals in two late-phase studies on patients, Lilly said. The ... [Published Indianapolis Star - Apr 16 2013]

Entities: Eli Lilly & Company, Diabetes, Drugs

First reported Jan 08 2013 - Updated Jan 08 2013 - 1 reports

Eli Lilly & Company

Eli Lilly reassumes development of LY2605541

Eli Lilly and Company has reassumed the worldwide development and commercialization rights for novel basal insulin analog giving a scope to diabetes alliance signed with Boehringer concerning LY2605541.Lilly also considers initiating remaining pre-planned ... [Published Pharmaceutical Business Review - Jan 08 2013]

Entities: Eli Lilly & Company, Diabetes, Enrique Conterno

More Content

sort by: Date \| Relevance
Lilly broadens diabetes offer with eye on bigge... [Published Reuters - May 03 2013]
Positive Phase III Results for Lilly's Dulaglut... [Published Pharmaceutical Technology - Apr 18 2013]
Eli Lilly reports top-line results of AWARD tri... [Published PharmaBiz - Apr 18 2013]
Lilly diabetes drug dulaglutide meets late-stag... [Published Diabetes.co.uk - Apr 17 2013]
Eli Lilly's experimental diabetes drug meets goals [Published Indianapolis Star - Apr 16 2013]
Lilly Releases Positive Phase 3 Data [Published Drug Discovery and Development - Apr 16 2013]
Eli Lilly scores upbeat PhIII data for GLP-1 dr... [Published FierceBiotech - Apr 16 2013]
Eli Lilly Diabetes Drug Meets Primary Efficacy ... [Published RTTNews.com - Apr 16 2013]
ELI LILLY & CO.: Lilly Announces Positive Resul... [Published 4 Traders - Apr 16 2013]
Lilly Announces Positive Results of Phase III T... [Published ADVFN UK - Apr 16 2013]
Eli Lilly reassumes sole worldwide rights for b... [Published PharmaBiz - Jan 09 2013]
Boehringer Ingelheim, Eli Lilly report positive... [Published PharmaBiz - Jan 09 2013]
Eli Lilly reassumes development of LY2605541 [Published Pharmaceutical Business Review - Jan 08 2013]
Lilly Diabetes joins with American Diabetes Ass... [Published PharmaBiz - Nov 29 2012]